Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan

Chien-Yuan Chen, Wang-Huei Sheng, Aristine Cheng, Yee-Chun Chen, Woei Tsay, Jih-Luh Tang, Shang-Yi Huang, Shan-Chwen Chang, Hwei-Fang Tien, Chien-Yuan Chen, Wang-Huei Sheng, Aristine Cheng, Yee-Chun Chen, Woei Tsay, Jih-Luh Tang, Shang-Yi Huang, Shan-Chwen Chang, Hwei-Fang Tien

Abstract

Background: Risk factors and outcomes in hematological patients who acquire invasive fungal sinusitis (IFS) are infrequently reported in the modern medical era.

Method: A retrospective study of hospitalized patients with hematological disease was conducted at National Taiwan University Hospital between January 1995 and December 2009.

Results: Clinical characteristics and outcomes with their associated radiographic and microbiological findings were analyzed. Forty-six patients with IFS and 64 patients with chronic non-invasive sinusitis were enrolled as comparsion. IFS developed more commonly in patients with acute myeloid leukemia (AML) and with prolonged neutropenia (absolute neutrophil count less than 500/mm³ for more than 10 days) (p < 0.001). Aspergillus flavus was the most common pathogen isolated (44%). Serum Aspergillus galactomannan antigen was elevated in seven of eleven patients (64%) with IFS caused by aspergillosis but negative for all three patients with mucormycosis. Bony erosion and extra-sinus infiltration was found in 15 of 46 (33%) patients on imaging. Overall, 19 of 46 patients (41.3%) died within 6 weeks. Patients with disease subtype of AML (p = 0.044; Odds Ratio [OR], 5.84; 95% confidence interval [95% CI], 1.02-30.56) and refractory leukemia status (p = 0.05; OR, 4.27; 95% CI, 1.003-18.15) had worse prognosis. Multivariate analysis identified surgical debridement as an independent good prognostic factor (p = 0.047) in patients with IFS.

Conclusions: Patients of AML with prolonged neutropenia (> 10 days) had significantly higher risk of IFS. Early introduction of anti-fungal agent and aggressive surgical debridement potentially decrease morbidity and mortality in high risk patients with IFS.

References

    1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237. doi: 10.1002/cncr.11882.
    1. Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: etiology, prevention, and treatment. Lancet Oncol. 2003;4:595–604. doi: 10.1016/S1470-2045(03)01218-X.
    1. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect. 2005;11(Suppl 5):24–29.
    1. Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis. 2009;22:385–393. doi: 10.1097/QCO.0b013e32832e074d.
    1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7–14. doi: 10.1086/323335.
    1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821. doi: 10.1086/588660.
    1. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol. 2002;81:233–243. doi: 10.1007/s00277-002-0466-3.
    1. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia--new drugs and immunotherapy. Best Pract Res Clin Haematol. 2008;21:683–690. doi: 10.1016/j.beha.2008.10.001.
    1. deShazo RD, Chapin K, Swain RE. Fungal sinusitis. N Engl J Med. 1997;337:254–259. doi: 10.1056/NEJM199707243370407.
    1. Parikh SL, Venkatraman G, DelGaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004;18:75–81.
    1. Anselmo-Lima WT, Lopes RP, Valera FC, Demarco RC. Invasive fungal rhinosinusitis in immunocompromised patients. Rhinology. 2004;42:141–144.
    1. Howells RC, Ramadan HH. Usefulness of computed tomography and magnetic resonance in fulminant invasive fungal rhinosinusitis. Am J Rhinol. 2001;15:255–261.
    1. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044–1051. doi: 10.1017/S0950268809991208.
    1. Iwen PC, Rupp ME, Hinrichs SH. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis. 1997;24:1178–1184. doi: 10.1086/513662.
    1. Drakos PE, Nagler A, Or R, Naparstek E, Kapelushnik J, Engelhard D, Rahav G, Ne'emean D, Slavin S. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1993;12:203–208.
    1. Saah D, Drakos PE, Elidan J, Braverman I, Or R, Nagler A. Rhinocerebral aspergillosis in patients undergoing bone marrow transplantation. Ann Otol Rhinol Laryngol. 1994;103:306–310.
    1. Talbot GH, Huang A, Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis. 1991;13:219–232. doi: 10.1093/clinids/13.2.219.
    1. Weber RS, Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987;97:937–941.
    1. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–1466. doi: 10.1086/516480.
    1. Ruhnke M, Böhme A, Buchheidt D, Donhuijsen K, Einsele H, Enzensberger R, Glasmacher A, Gümbel H, Heussel CP, Karthaus M, Lambrecht E, Südhoff T, Szelényi H. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol. 2003;82(Suppl 2):S141–148.
    1. Lanza DC, Dhong HJ, Tantilipikorn P, Tanabodee J, Nadel DM, Kennedy DW. Fungus and chronic rhinosinusitis: from bench to clinical understanding. Ann Otol Rhinol Laryngol. 2006;196(Suppl):27–34.
    1. Li Y, Li Y, Li P, Zhang G. Diagnosis and endoscopic surgery of chronic invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2009;23:622–625. doi: 10.2500/ajra.2009.23.3361.
    1. Ingley AP, Parikh SL, DelGaudio JM. Orbital and cranial nerve presentations and sequelae are hallmarks of invasive fungal sinusitis caused by Mucor in contrast to Aspergillus. Am J Rhinol. 2008;22:155–158. doi: 10.2500/ajr.2008.22.3141.
    1. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses. 2009;52:206–22. doi: 10.1111/j.1439-0507.2008.01642.x.
    1. Surya Prakash Rao G, Mann SB, Talwar P, Arora MM. Primary mycotic infection of paranasal sinuses. Mycopathologia. 1984;84:73–76. doi: 10.1007/BF00436515.
    1. Bethge WA, Schmalzing M, Stuhler G, Schumacher U, Kröber SM, Horger M, Einsele H, Kanz L, Hebart H. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematologica. 2005;90(Suppl):ECR22.
    1. Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, Molteni A, Morra E. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica. 2000;85:1068–1071.
    1. Suslu AE, Ogretmenoglu O, Suslu N, Yucel OT, Onerci TM. Acute invasive fungal rhinosinusitis: our experience with 19 patients. Eur Arch Otorhinolaryngol. 2009;266:77–82. doi: 10.1007/s00405-008-0694-9.
    1. Hachem RY, Boktour MR, Hanna HA, Husni R, Hanna EY, Keutgen X, Shukrallah B, Raad II. Sinus surgery combined with antifungal therapy is effective in the treatment of invasive Aspergillus sinusitis in neutropenic patients with cancer. Infection. 2008;36:539–542. doi: 10.1007/s15010-008-7388-5.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever